Literature DB >> 31515405

Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension.

Cheng-Jun Hu1,2,3,4, Jens M Poth2,5,3, Hui Zhang2, Amanda Flockton2, Aya Laux1, Sushil Kumar2, Brittany McKeon2, Gary Mouradian2, Min Li2, Suzette Riddle2, Steven C Pugliese2, R Dale Brown2, Eli M Wallace6, Brian B Graham2, Maria G Frid2, Kurt R Stenmark7,4.   

Abstract

Most published studies addressing the role of hypoxia inducible factors (HIFs) in hypoxia-induced pulmonary hypertension development employ models that may not recapitulate the clinical setting, including the use of animals with pre-existing lung/vascular defects secondary to embryonic HIF ablation or activation. Furthermore, critical questions including how and when HIF signalling contributes to hypoxia-induced pulmonary hypertension remain unanswered.Normal adult rodents in which global HIF1 or HIF2 was inhibited by inducible gene deletion or pharmacological inhibition (antisense oligonucleotides (ASO) and small molecule inhibitors) were exposed to short-term (4 days) or chronic (4-5 weeks) hypoxia. Haemodynamic studies were performed, the animals euthanised, and lungs and hearts obtained for pathological and transcriptomic analysis. Cell-type-specific HIF signals for pulmonary hypertension initiation were determined in normal pulmonary vascular cells in vitro and in mice (using cell-type-specific HIF deletion).Global Hif1a deletion in mice did not prevent hypoxia-induced pulmonary hypertension at 5 weeks. Mice with global Hif2a deletion did not survive long-term hypoxia. Partial Hif2a deletion or Hif2-ASO (but not Hif1-ASO) reduced vessel muscularisation, increases in pulmonary arterial pressures and right ventricular hypertrophy in mice exposed to 4-5 weeks of hypoxia. A small molecule HIF2 inhibitor (PT2567) significantly attenuated early events (monocyte recruitment and vascular cell proliferation) in rats exposed to 4 days of hypoxia, as well as vessel muscularisation, tenascin C accumulation and pulmonary hypertension development in rats exposed to 5 weeks of hypoxia. In vitro, HIF2 induced a distinct set of genes in normal human pulmonary vascular endothelial cells, mediating inflammation and proliferation of endothelial cells and smooth muscle cells. Endothelial Hif2a knockout prevented hypoxia-induced pulmonary hypertension in mice.Inhibition of HIF2 (but not HIF1) can provide a therapeutic approach to prevent the development of hypoxia-induced pulmonary hypertension. Future studies are needed to investigate the role of HIFs in pulmonary hypertension progression and reversal.
Copyright ©ERS 2019.

Entities:  

Year:  2019        PMID: 31515405      PMCID: PMC6911916          DOI: 10.1183/13993003.00378-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  44 in total

Review 1.  HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease.

Authors:  Larissa A Shimoda; Gregg L Semenza
Journal:  Am J Respir Crit Care Med       Date:  2011-01-15       Impact factor: 21.405

2.  Apoptosis Signal-Regulating Kinase 1 Inhibition in Pulmonary Hypertension. Too Much to ASK?

Authors:  Martin R Wilkins
Journal:  Am J Respir Crit Care Med       Date:  2018-02-01       Impact factor: 21.405

3.  Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Authors:  Kevin D Courtney; Jeffrey R Infante; Elaine T Lam; Robert A Figlin; Brian I Rini; James Brugarolas; Naseem J Zojwalla; Ann M Lowe; Keshi Wang; Eli M Wallace; John A Josey; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2017-12-19       Impact factor: 44.544

4.  Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α.

Authors:  Molly K Ball; Gregory B Waypa; Paul T Mungai; Jacqueline M Nielsen; Lyubov Czech; V Joseph Dudley; Lauren Beussink; Robert W Dettman; Sara K Berkelhamer; Robin H Steinhorn; Sanjiv J Shah; Paul T Schumacker
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

5.  Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension.

Authors:  N Gambaryan; F Perros; D Montani; S Cohen-Kaminsky; M Mazmanian; J-F Renaud; G Simonneau; A Lombet; M Humbert
Journal:  Eur Respir J       Date:  2010-09-30       Impact factor: 16.671

6.  A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development.

Authors:  M Ema; S Taya; N Yokotani; K Sogawa; Y Matsuda; Y Fujii-Kuriyama
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

7.  CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension.

Authors:  Yen-Rei A Yu; Lan Mao; Claude A Piantadosi; Michael D Gunn
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

8.  Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension.

Authors:  Wen Tian; Xinguo Jiang; Rasa Tamosiuniene; Yon K Sung; Jin Qian; Gundeep Dhillon; Lajos Gera; Laszlo Farkas; Marlene Rabinovitch; Roham T Zamanian; Mohammed Inayathullah; Marina Fridlib; Jayakumar Rajadas; Marc Peters-Golden; Norbert F Voelkel; Mark R Nicolls
Journal:  Sci Transl Med       Date:  2013-08-28       Impact factor: 17.956

Review 9.  The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.

Authors:  Steven C Pugliese; Jens M Poth; Mehdi A Fini; Andrea Olschewski; Karim C El Kasmi; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-21       Impact factor: 5.464

Review 10.  Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension.

Authors:  Cheng-Jun Hu; Hui Zhang; Aya Laux; Soni S Pullamsetti; Kurt R Stenmark
Journal:  J Physiol       Date:  2018-08-07       Impact factor: 5.182

View more
  26 in total

Review 1.  Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia.

Authors:  Larissa A Shimoda
Journal:  Physiology (Bethesda)       Date:  2020-07-01

Review 2.  Hypoxia-inducible factor signaling in pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Argen Mamazhakypov; Norbert Weissmann; Werner Seeger; Rajkumar Savai
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

3.  Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine.

Authors:  M Patricia George; Mark T Gladwin; Brian B Graham
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

Review 4.  Turning the Oxygen Dial: Balancing the Highs and Lows.

Authors:  Alan H Baik; Isha H Jain
Journal:  Trends Cell Biol       Date:  2020-05-05       Impact factor: 20.808

5.  Role of Hypoxia-Inducible Factors in Regulating Right Ventricular Function and Remodeling during Chronic Hypoxia-induced Pulmonary Hypertension.

Authors:  Kimberly A Smith; Gregory B Waypa; V Joseph Dudley; G R Scott Budinger; Hiam Abdala-Valencia; Elizabeth Bartom; Paul T Schumacker
Journal:  Am J Respir Cell Mol Biol       Date:  2020-11       Impact factor: 6.914

6.  Perinatal Hypoxia-Inducible Factor Stabilization Preserves Lung Alveolar and Vascular Growth in Experimental Bronchopulmonary Dysplasia.

Authors:  Kellen Hirsch; Elizabeth Taglauer; Gregory Seedorf; Carly Callahan; Erica Mandell; Carl W White; Stella Kourembanas; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

Review 7.  Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization.

Authors:  Nunziata Maio; De-Liang Zhang; Manik C Ghosh; Anshika Jain; Anna M SantaMaria; Tracey A Rouault
Journal:  Semin Hematol       Date:  2021-06-27       Impact factor: 3.754

Review 8.  Hypoxia and the integrated stress response promote pulmonary hypertension and preeclampsia: Implications in drug development.

Authors:  Xiang-Qun Hu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2021-07-22       Impact factor: 7.851

9.  Perinatal Hypoxemia and Oxygen Sensing.

Authors:  Gary C Mouradian; Satyan Lakshminrusimha; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

10.  Endothelial cell PHD2-HIF1α-PFKFB3 contributes to right ventricle vascular adaptation in pulmonary hypertension.

Authors:  Biruk Kassa; Rahul Kumar; Claudia Mickael; Linda Sanders; Christine Vohwinkel; Michael H Lee; Sue Gu; Jens M Poth; Kurt R Stenmark; You-Yang Zhao; Rubin M Tuder; Brian B Graham
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-08-04       Impact factor: 6.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.